Project financed by the Medical Research Agency!
Scientific consortium comprising: Department of Recombinant Vaccines (Intercollegiate Faculty of Biotechnology University of Gdansk and Medical University of Gdansk), Institute of Biochemistry and Biophysics of Polish Academy of Sciences in Warsaw and pharmaceutical company Adamed obtained a grant from Medical Research Agency (ABM) within the frame of the call “Development of innovative therapeutic solutions based on RNA technology”.
The scientific aim of the consortium is to reach the stage of clinical studies for potential antiviral vaccines based on mRNA and virus-like particles (VLP) technology. Three pathogens causing major zoonoses : SARS-CoV-2 virus, TBEV (tick-borne encephalitis virus) and West Nile virus were selected as major targets.
The total budget of the project is 88 mln PLN, total ABM contribution – 58.5 mln PLN, out of this sum – 11.5 mln PLN for the University of Gdansk.